Premium
MYB, CD117 and SOX‐10 expression in cutaneous adnexal tumors
Author(s) -
Evangelista Mara Therese P.,
North Jeffrey P.
Publication year - 2017
Publication title -
journal of cutaneous pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 75
eISSN - 1600-0560
pISSN - 0303-6987
DOI - 10.1111/cup.12904
Subject(s) - cd117 , pathology , apocrine , medicine , cylindroma , carcinoma , myb , biology , cd34 , gene expression , biochemistry , genetics , stem cell , gene
Background Elevated MYB expression has been documented in adenoid cystic carcinoma (ACC), cylindroma, and spiradenoma, but the specificity of this finding is unknown. CD117 and SOX‐10 expression also occurs in some cutaneous adnexal tumors. This study assesses MYB, CD117 and SOX‐10 expression in cutaneous adnexal tumors. Methods Retrospective analysis of 184 benign adnexal tumors (140 eccrine/apocrine, 40 follicular and 10 sebaceous), and 30 malignant adnexal tumors was performed with MYB, SOX‐10 and CD117 immunostaining. Results In the benign adnexal tumors, 16% (23/140) significantly expressed MYB. MYB expression was limited to cylindromas and to a lesser extent, spiradenomas in the benign cohort. Elevated MYB expression was detected in mucinous carcinoma, endocrine mucin‐producing sweat gland carcinoma and 1 and 4 cases of extramammary Paget's disease (EMPD) in the malignant cohort. CD117 and SOX‐10 had similar overall positivity rates in benign apocrine and eccrine tumors (45% and 68% respectively), and were generally negative in other benign and malignant adnexal tumors. Conclusion Expression of MYB appears limited to a small number of cutaneous adnexal tumors, including cylindromas, spiradenomas, ACCs, mucinous carcinoma, endocrine mucin‐producing sweat gland carcinoma and some cases of EMPD.